Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms LAUREL
- Sponsors Roche
- 24 Apr 2019 Planned End Date changed from 20 Aug 2020 to 21 Jul 2020.
- 24 Apr 2019 Planned primary completion date changed from 20 Aug 2020 to 21 Apr 2020.
- 11 Feb 2019 Status changed from recruiting to active, no longer recruiting.